Ablation Systems

This channel provides technology news on new ablation system advances in cardiac electrophysiology (EP) used to treat dysfunctional heart tissue that cause arrhythmias. Each cell in the myocardium generates its own electrical impulses to cause the heart to beat, but if some cells generate signals that are not in synch with other parts of the heart, it causes an arrhythmia, an abnormal heart beat. Ablation systems use heat (usually generated  by radio frequency, RF, energy or a laser) or extreme cold to cause small burns. These lesions create scar tissue that block electrical signals causing the arrhythmia. These procedures are guided by EP electro mapping systems

Computer Simulations May Treat Most Common Heart Rhythm Disorder

The OPTIMA (Optimal Target Identification via Modelling of Arrhythmogenesis) simulator uses contrast-enhanced MRI scans to create personalized digital replicas of a patient's heart to guide catheter abation for atrial fibrillation. Image courtesy of Patrick M. Boyle and Natalia A. Trayanova.

News | EP Mapping and Imaging Systems | August 19, 2019
August 19, 2019 — Scientists at Johns Hopkins have successfully created personalized digital replicas of the upper...
Videos | EP Lab | July 26, 2019
Mark Ibrahim, M.D., FACC, assistant professor of medicine and radiology, associate program director, advanced cardiac...
Videos | EP Lab | July 25, 2019
Pierre Qian, MBBS, cardiac electrophysiologist fellow, Brigham and Women's Hospital, explains how his facility is...
Dr. Markus Krane, deputy director of the Cardiac and Vascular Surgery Unit at the DHM helped compile an atlas of the heart and discovered myosin binding protein H-like (MYBPHL) occurs only in the atria of the heart. Researchers began using it as a blood test biomarker to assess the success of atrial fibrillation ablation procedures.

Dr. Markus Krane, deputy director of the Cardiac and Vascular Surgery Unit at the DHM helped compile an atlas of the heart and discovered myosin binding protein H-like (MYBPHL) occurs only in the atria of the heart. Researchers began using it as a blood test biomarker to assess the success of atrial fibrillation ablation procedures.

Feature | Atrial Fibrillation | July 24, 2019
July 24, 2019 — Atrial fibrillation (AFib) is a common abnormal heart rhythm. It is treated either with medications or...
Charge Density Mapping Eliminates Repeat Ablation for Atrial Fibrillation at One Year
News | EP Mapping and Imaging Systems | July 15, 2019
July 15, 2019 — Acutus Medical announced the publication of the UNCOVER AF study in Circulation: Arrhythmia and...
VIVO 3-D Cardiac Mapping System Cleared by FDA
Technology | EP Mapping and Imaging Systems | July 01, 2019
July 1, 2019 — Catheter Precision Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared its new...
Boston Scientific Initiates OPTION Trial of Watchman FLX
News | Left Atrial Appendage (LAA) Occluders | June 12, 2019
June 12, 2019 — Boston Scientific Corp. has initiated the OPTION trial to compare safety and effectiveness of the next-...
Algorithm Steers Catheters to Right Spot to Treat Atrial Fibrillation

Using human AFib simulations, the researchers demonstrated that their technique can stop the catheter at the right target and identify the source type with a 95.25 percent success rate. This new algorithm also is effective in scarred tissue, which makes ablation more challenging, and has a 99 percent detection rate regardless of the scar size. Image courtesy of Florida Atlantic University.

News | EP Mapping and Imaging Systems | May 28, 2019
May 28, 2019 — Researchers have developed the first algorithm that can locate patient-specific ablation targets for...
Acutus Medical Announces Rhythm Xience Acquisition, New Partnerships at HRS 2019

Acutus Medical's acquisition of Rhythm Xience brings the Flextra steerable introducer sheath into Acutus Medical's product portfolio.

News | EP Mapping and Imaging Systems | May 17, 2019
May 17, 2019 — At the 40th annual Heart Rhythm Scientific Sessions, May 8-11 in San Francisco, Acutus Medical announced...
Biosense Webster Launches Cartonet Analytics Software for Electrophysiology
Technology | Analytics Software | May 16, 2019
May 16, 2019 — Johnson & Johnson Medical Devices Companies announced the launch of Biosense Webster Inc.’s Cartonet...
Biosense Webster Announces Initial Results From First-in-Human QDOT-FAST Study
News | Ablation Systems | May 16, 2019
May 16, 2019 — Johnson & Johnson Medical Devices Companies announced that Biosense Webster, Inc.’s QDot Micro...
CardioFocus Announces Results From HeartLight X3 Ablation System Pivotal Study
News | Ablation Systems | May 16, 2019
May 16, 2019 — CardioFocus Inc. announced the presentation of results from its pivotal confirmatory study evaluating...
The ERADICATE-AF Trial combined pulmonary vein isolation with renal denervation therapy and showed imporve outcomes.
News | Atrial Fibrillation | May 15, 2019 | Dave Fornell, Editor
May 15, 2019 — Renal artery denervation (RDN) was found to be safe when employed with pulmonary vein isolation (PVI) to...
An screen shot of the Abbott Focal Impulse and Rotor Modulated (FIRM)-guided ablation system used to guide AF ablation procedures.

An screen shot of the Abbott Focal Impulse and Rotor Modulated (FIRM)-guided ablation system used to guide AF ablation procedures. 

News | Atrial Fibrillation | May 14, 2019 | Dave Fornell, Editor
May 14, 2019 – The first prospective, multicenter, randomized, controlled trial to compare conventional pulmonary vein...
New Global Consensus Statement Addresses Catheter Ablation of Ventricular Arrhythmias
News | Ablation Systems | May 14, 2019
May 14, 2019 — The Heart Rhythm Society (HRS) in partnership with three other professional societies issued an...